DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for pleomorphic liposarcoma — screening already-approved drugs against its 31-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePleomorphic liposarcoma maps to a 31-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pleomorphic liposarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lysine demethylase 6A (KDM6A) — KDM6A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet e7zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FUL · 1.649 Å · ligand 1-methyl-5-oxidanyl-4-oxidanylidene-pyridine-2-carboxylic acid (E7Z). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Orthopaedic Surgery and Research · 2021 · 17 citations · open access
Survivorship and prognostic factors for pleomorphic liposarcoma: a population-based study
AbstractBACKGROUND: Pleomorphic liposarcoma is the least common but most aggressive subtype of liposarcoma. Very few studies have presented data on pleomorphic liposarcoma specifically, often including a limited number of cases and short-term follow-up. As a result, the survivorship and prognostic characteristics of this tumor remain incompletely identified. STUDY DESIGN AND SETTING: Cross-sectional analysis of the Surveillance Epidemiology and End Results database (1996-2015). RESULTS: Overall survival for the entire series was 54% (95% confidence interval [CI], 49-58%) and 40% (95% CI, 35-45%) at 5 and 10 years, respectively. Disease-specific survival for the entire series was 60% (95% CI, 56-65%) and 53% (95% CI, 48-58%) at 5 and 10 years, respectively. Patients who survived 10 years or more were more likely to die of events unrelated to pleomorphic liposarcoma. Univariate and multivariate analysis demonstrated that not receiving cancer-directed surgery was an independent poor prognostic factor. Older age (≥ 65 years old) was associated with worse overall survival but not disease-specific survival. Tumor stage and radiotherapy showed different impact on survival depending on tumor size. In comparison to localized staged tumors, regional stage only predicts poor survival in patients with tumor size less than 5 cm, while distant stage is an independent worse prognosis factor. Radiotherapy only benefits patients with tumor size larger than 10 cm. These results were confirmed in competing risk analysis. CONCLUSION: Survival rates of patients with pleomorphic liposarcoma has not changed over the past 20 years. Patients with distant stage have poor prognosis; regional stage indicates worse survival in patients with tumor size less than 5 cm. Receiving surgery could prolong the survival, while radiotherapy only benefits patients with large tumor size (> 10 cm). Older age is associated with poor overall survival but not disease-specific survival. Routine patient surveillance following initial diagnosis should at least be 10 years for pleomorphic liposarcoma.
International Journal of Surgery Case Reports · 2023 · 2 citations · open access
Primary pleomorphic liposarcoma of bone: A case report with literature review
AbstractINTRODUCTION AND IMPORTANCE: Primary pleomorphic liposarcoma of bone is an exceedingly rare sarcoma. CASE PRESENTATION: We herein report the case of a primary pleomorphic liposarcoma of the distal femur in a 20-year-old female patient. Magnetic resonance imaging showed a 25.4-mm medullary necrotic tumor process in the lower third of the distal right femoral meta-diaphysis that was weakly enhanced after gadolinium injection. The patient first underwent an open biopsy. Microscopically, a pleomorphic liposarcoma were suspected. Immunohistochemically, tumor cells expressed the S-100 protein. Fluorescent in situ hybridization showed the absence of MDM2 gene amplification and the absence of EWING/PNET translocation. The diagnosis of primary pleomorphic liposarcoma of the bone was then retained. A wide resection and chemotherapy were performed. The patient died of liver metastasis after 8 months of follow-up. CLINICAL DISCUSSION AND CONCLUSION: Primary pleomorphic liposarcoma has no specific clinical or radiological findings. Histological diagnosis and molecular study are crucial tools for making an accurate diagnosis.
Asian Cardiovascular and Thoracic Annals · 2019 · 1 citations
Pleomorphic liposarcoma of chest wall: a rare entity with challenging management
AbstractPleomorphic liposarcoma is the rarest subtype of liposarcoma, with a high recurrence rate and poor prognosis. We present the case of young man with a rapidly growing large anterior chest wall liposarcoma that was excised, but he suffered 3 local recurrences in one year, showing the aggressive nature of the disease. If not completely resected with a tumor-free margin, the patient may have to endure multiple extensive surgeries in quick succession, increasing the chances of metastasis and a fatal outcome. Pleomorphic liposarcoma should be radically excised along with radiotherapy and strict follow-up of such patients.
[Relapsed Pleomorphic Liposarcoma with Mediastinal Metastasis: A Case Report and Review of the Literature].
AbstractMetastatic pleomorphic liposarcoma in the mediastinum is rare, and the current treatments are most of the times ineffective. We hereby report a case with relapsed pleomorphic liposarcoma adjacent to the psoas major muscle and with mediastinal metastasis, to discuss the clinical features and treatment strategies of pleomorphic liposarcoma. The patient's clinical history, imaging findings, pathological diagnosis, and multidisciplinary treatments were retrospectively analyzed. A 41-year old female patient was diagnosed with pleomorphic liposarcoma adjacent to the psoas major muscle and mediastinal metastasis. After multidisciplinary treatments, including surgery, chemotherapy, and targeted therapy, the patient has survived 65 months until now. Surgical resection is considered as the first choice of the treatment for pleomorphic liposarcoma. Multidisciplinary treatments, including chemotherapy and other medical treatments, are effective to slow the disease progression and to reduce the disease recurrence.
Cell & Cellular Life Sciences Journal · 2023 · 1 citations · open access
The Unctuous Unconformity-Pleomorphic Liposarcoma
AbstractLiposarcoma was initially scripted by Rudolph Virchowin 1857. Subsequently, Franz Michael Enzinger and DonaldJ Winslow described pleomorphic liposarcoma and diversesubtypes of liposarcoma in 1962. Epithelioid pleomorphicliposarcoma was pre-eminently denominated by MarkkuMiettinen and Franz Michael Enzinger in 1999. Pleomorphicliposarcoma represents as an exceptional, high grade,malignant neoplasm emerging from adipocytic tissues.Characteristically, the high grade pleomorphic liposarcomais constituted of variably quantifiable pleomorphic lipoblastswith absent foci of well differentiated liposarcoma or diverselineages of cellular differentiation. The neoplasm is devoidof areas which simulate atypical lipomatous tumour / welldifferentiated liposarcoma or diverse foci of mesenchymaldifferentiation.
Survivorship and prognostic factors for pleomorphic liposarcoma: a population-based study
AbstractAbstract Background Pleomorphic liposarcoma is the least common but most aggressive subtype of liposarcoma. Very few studies have presented data on pleomorphic liposarcoma specifically, often including a limited number of cases and short-term follow-up. As a result, the survivorship and prognostic characteristics of this tumor remain incompletely identified. Study design and setting Cross-sectional analysis of the Surveillance Epidemiology and End Results database (1996–2015). Results Overall survival for the entire series was 54% (95% confidence interval [CI], 49–58%) and 40% (95% CI, 35–45%) at 5 and 10 years, respectively. Disease-specific survival for the entire series was 60% (95% CI, 56–65%) and 53% (95% CI, 48–58%) at 5 and 10 years, respectively. Patients who survived 10 years or more were more likely to die of events unrelated to pleomorphic liposarcoma. Univariate and multivariate analysis demonstrated that not receiving cancer-directed surgery was an independent poor prognostic factor. Older age (≥ 65 years old) was associated with worse overall survival but not disease-specific survival. Tumor stage and radiotherapy showed different impact on survival depending on tumor size. In comparison to localized staged tumors, regional stage only predicts poor survival in patients with tumor size less than 5 cm, while distant stage is an independent worse prognosis factor. Radiotherapy only benefits patients with tumor size larger than 10 cm. These results were confirmed in competing risk analysis. Conclusion Survival rates of patients with pleomorphic liposarcoma has not changed over the past 20 years. Patients with distant stage have poor prognosis; regional stage indicates worse survival in patients with tumor size less than 5 cm. Receiving surgery could prolong the survival, while radiotherapy only benefits patients with large tumor size (> 10 cm). Older age is associated with poor overall survival but not disease-specific survival. Routine patient surveillance following initial diagnosis should at least be 10 years for pleomorphic liposarcoma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
